Emergent BioSolutions layoffs, on the record
Every job cut, severance charge and restructuring Emergent BioSolutions reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 1,600 to approximately 900.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 1,600 | December 31, 2023 |
| 10-K for 2024 | approximately 900 | December 31, 2024 |
Job cuts, severance and restructuring
Our summaryInitiated the January 2023 organizational restructuring plan to cut operating costs and improve margins, reducing the workforce by about 125 employees.
Word for word“As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees.” 10-K for 2023
Our summaryInitiated the August 2023 restructuring plan to reduce investment in and de-emphasize the Bioservices business, reducing the workforce by about 400 employees.
Word for word“As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees.” 10-K for 2023
Our summaryInitiated the May 2024 restructuring plan, cutting the workforce, eliminating vacant positions and closing the Baltimore-Bayview and Rockville facilities.
Word for word“These strategic actions led to a reduction of the Company's workforce by approximately 300 employees across all areas of the Company and the elimination of approximately 85 positions that were vacant, as well as the closure of the Company's Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility.” 10-K for 2024
Our summaryInitiated the August 2024 restructuring plan at the Lansing facility, reducing the workforce and eliminating several open positions.
Word for word“In August 2024, the Company initiated the August 2024 Plan at the Company's Lansing facility, which reduced the Company's workforce by approximately 70 employees, as well as eliminated several open positions.” 10-K for 2024
Our summarySold the Drug Product facility in Baltimore-Camden to Bora Pharmaceuticals Injectables Inc.
Word for word“As a result of the divestiture, the Company recognized a loss on sale of business of $36.5 million, net of transaction costs of $3.8 million, during the year ended December 31, 2024.” 10-K for 2024
Our summaryReported that employee count declined during 2024 due to the May and August 2024 restructurings and facility sales, and that impacted employees received transition services, severance and benefits.
Word for word“During 2024, our number of employees declined by approximately 700 due to the organizational restructurings announced in May and August 2024, the sale of our Hattiesburg facility in July 2024, and the sale of our Camden Manufacturing facility to Bora in August 2024.” 10-K for 2024
| Fiscal year ended | Restructuring charges |
|---|---|
| 2023-12-31 | $29.3 million |
| 2024-12-31 | $22.5 million |
| 2025-12-31 | −$2.1 million |
Emergent BioSolutions filed 4 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Emergent BioSolutions’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-27. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.